This document is an official guidance from the U.S. Food and Drug Administration (FDA) issued in December 2025. It provides the agency’s current recommendations and interpretations on how clinical investigators (the doctors/researchers running clinical trials) should handle safety reporting for drugs and medical devices that are still under investigation.
Purpose & Scope
- Primary Goal: To help clinical investigators comply with federal safety reporting regulations for:
- Drug/Biological Product Trials: Studies conducted under an Investigational New Drug Application (IND).
- Medical Device Trials: Studies conducted under an Investigational Device Exemption (IDE).
- Key Audience: Clinical Investigators, Industry Sponsors, and Institutional Review Boards (IRBs).
- Legal Status: It contains “nonbinding recommendations.” This means it explains the FDA’s thinking and suggests best practices, but investigators can use alternative approaches if they still meet the legal requirements (found in the Code of Federal Regulations, Title 21).
Core Concepts and Definitions
The guidance clarifies critical terms that dictate reporting obligations:
For Drugs:
- Adverse Event (AE): Any unfavorable medical occurrence during drug use, regardless of suspected cause.
- Suspected Adverse Reaction: An adverse event where there is a “reasonable possibility” (evidence to suggest) a causal relationship with the drug.
- Serious Adverse Event (SAE): An event that results in death, is life-threatening, requires hospitalization, causes significant disability, or is a congenital anomaly. It also includes important medical events that could jeopardize the patient.
For Devices:
- Unanticipated Adverse Device Effect (UADE): A serious adverse effect on health or safety that is not previously identified in nature, severity, or frequency in the study’s investigational plan. It is, by definition, both serious and unexpected in the context of the study.
Key Investigator Responsibilities
The guidance outlines a clear framework for what investigators must do.
A. Reporting to the Sponsor (the company or entity managing the trial):
- For IND (Drug) Studies: Investigators must immediately report all Serious Adverse Events (SAEs) to the sponsor, whether or not they think it’s drug-related. They must also provide an assessment of whether there is a “reasonable possibility” the drug caused it.
- “Immediately” is interpreted as as soon as feasible, generally within 1 calendar day.
- Non-serious AEs are reported according to the protocol’s schedule.
- For IDE (Device) Studies: Investigators must report Unanticipated Adverse Device Effects (UADEs) to the sponsor within 10 working days of learning about them.
B. Reporting to the Institutional Review Board (IRB):
- Investigators must promptly report any “unanticipated problems involving risk to human participants.”
- The FDA clarifies that for drug trials, all IND safety reports received from the sponsor and all SAEs from certain bioavailability studies qualify as such unanticipated problems and must be sent to the IRB.
- Other problems like protocol deviations, privacy breaches, or serious screening-related injuries must also be reported to the IRB.
C. Reviewing Safety Reports from the Sponsor:
- Investigators have a duty to review all safety reports (IND safety reports, UADE reports) sent by the sponsor. This is critical for protecting the rights and welfare of the participants currently under their care in the trial.
Critical Distinction: Investigator vs. Sponsor Role
The guidance highlights a crucial division of labor in assessing safety:
- Investigator’s Role: To observe, document, and report all SAEs/UADEs promptly. They provide an initial, site-level causality assessment based on their direct knowledge of the participant.
- Sponsor’s Role: To aggregate data from all trial sites, analyze trends, and make the final determination on whether an event is a “suspected adverse reaction” (for drugs) or a UADE (for devices). The sponsor is responsible for reporting these assessed risks to the FDA and all investigators.
Why This Guidance is Important
This document is a key operational manual for clinical trial safety. It:
- Standardizes Practices: Ensures all investigators follow the same FDA-interpreted rules for what, when, and how to report.
- Protects Participants: Creates a clear chain for urgent safety information to flow from the investigator to the sponsor and IRB, enabling rapid response to potential risks.
- Ensures Data Quality: By requiring immediate reporting of SAEs and clear definitions, it helps build a reliable safety dataset for the FDA to evaluate whether a new drug or device should be approved.
In summary, this guidance places the clinical investigator as the essential first link in the pharmacovigilance chain for clinical trials, defining their critical responsibilities in detecting, reporting, and reacting to potential safety signals to protect trial participants.
